Vnitr Lek 2013, 59(4):249-255

Changes in weight and diabetes compensation (HbA_1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-II study (observations lasting 24 months)

J. Perušičová^1,*, P. Piťhová¹, I. Haladová², D. Ácsová, J. Bělobrádková, A. Belzová, K. Berková, B. Doležalová, H. Dvořáková, K. Hejnicová, M. Hudcová, D. Kallmünzerová, Z. Krejsová, G. Markofová, H. Müllerová, K. Owen, M. Pelikánová, L. Raclavská, E. Račická, O. Škarpová, A. Váchová, A. Veselá, J. Vyoralová, J. Brož, T. Edelsberger, M. Honka, T. Hrdina, P. Chmura, J. Tošovský

¹ Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA

² I. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Martin Matějovič, Ph.D.

BIBY-II study objective:
To obtain experience with long-term (24 months) exenatide treatment (Byetta) in patients with diabetes mellitus type 2 from a common clinical practice of diabetology departments in the Czech Republic.


Type of observation:
Observational study conducted by a randomly selected group of outpatient medical practitioners from 28 diabetology departments in the Czech Republic.


Observed and assessed population:
From the original population of 465 patients, who underwent a minimum of three month's Byetta treatment, 169 patients (36.6%) remained during the second prolonged observation after 18 months, and 76 patients completed 24 months of uninterrupted Byetta treatment. The following basic information about the patients was collected: year of birth, sex, age when diabetes mellitus (DM) manifested, height, maximum weight before diabetes and when DM manifested. The study recorded the following values in three-month intervals: weight, waistline, glycated haemoglobin (HbA_1c), and DM treatment. The population of the prolonged observation comprised 50.3% women and 49.7 % men, and the average age at the time of DM2 manifestation was 48.0 (20-73 years).

Results:
At the beginning of Byetta treatment, the average maximum BMI in the sub-population observed for 24 months was 38.44; after 3, 6, 9, 12 and 24 months the following levels were measured, respectively: 36.79, 36.22, 35.91, 35.57 and 35.58. The original HbA_1c level of 7.44% at the beginning of Byetta treatment decreased after 3, 6, 9, 12 and 24 months to 6.33, 5.98, 5.83, 5.86 and 5.93%.

Conclusion:
Adding Byetta to the currently applied treatment of obese patients with diabetes mellitus type 2 over a period of 24 months has led to an improvement in HbA_1c level by 1.51%, and BMI level was reduced by 2.37 after two years of Byetta treatment.

Keywords: diabetes mellitus type 2; change in weight of a diabetic; exenatide; Byetta; BMI; HbA_1c

Received: September 4, 2012; Accepted: January 17, 2013; Published: April 1, 2013  Show citation